A phase I/II dose-escalation multi-center study to evaluate the safety of infusion of natural killer cells or memory T cells as adoptive therapy in coronavirus pneumonia and/or lymphopenia: RELEASE study protocol

BACKGROUND: Moderate/severe cases of COVID-19 present a dysregulated immune system with T cell lymphopenia and a hyper-inflammatory state. This is a study protocol of an open-label, multi-center, double-arm, randomized, dose-finding phase I/II clinical trial to evaluate the safety, tolerability, all...

Descripción completa

Detalles Bibliográficos
Autores principales: García-García, I., Guerra-García, P., Ferreras, C., Borobia, A. M., Carcas, A. J., Queiruga-Parada, J., Vicario, J. L., Mirones, I., Solano, C., Eguizabal, C., Soria, B., Pérez-Martínez, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487326/
https://www.ncbi.nlm.nih.gov/pubmed/34600562
http://dx.doi.org/10.1186/s13063-021-05625-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487326/
https://www.ncbi.nlm.nih.gov/pubmed/34600562
http://dx.doi.org/10.1186/s13063-021-05625-7

Ejemplares similares